BioPharma Resources

Drug Trial Radar · NCT07863193

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design Trial to Evaluate the Safety and Efficacy of Denifanstat in Participants With Moderate to Severe Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Oct 21, 2026

Primary completion

Aug 2027

Study completion Apr 2028

Sponsor

Lead sponsor
Sagimet Biosciences Inc.Industry
Sponsor type
Industry
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age. After the 12-week treatment phase, a subset of approximately 530 participants will have the option to consent to an open-label extension phase for an additional 40 weeks of treatment.

Conditions

  • Acne Vulgaris

Interventions

  • DenifanstatDrug

    Oral, once daily

  • PlaceboOther

    Oral, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving EGSS success, defined as a score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from their baseline scoreTime frame: Week 12
  2. Absolute change from baseline in inflammatory lesion count (ILC)Time frame: Week 12
  3. Absolute change from baseline in non-inflammatory lesion count (ILC)Time frame: Week 12

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Sagimet Investigative Site

    Bryant, Arkansas · Recruiting

  • Sagimet Investigative Site

    Beverly Hills, California · Recruiting

  • Sagimet Investigative Site

    Fremont, California · Recruiting

  • Sagimet Investigative Site

    San Diego, California · Recruiting

  • Sagimet Investigative Site

    Santa Ana, California · Recruiting

  • Sagimet Investigative Site

    Doral, Florida · Recruiting

  • Sagimet Investigative Site

    Fort Lauderdale, Florida · Recruiting

  • Sagimet Investigative Site

    Miami, Florida · Recruiting

  • Sagimet Investigative Site

    Miami, Florida · Recruiting

  • Sagimet Investigative Site

    Miami, Florida · Recruiting

  • Sagimet Investigative Site

    Miami, Florida · Recruiting

  • Sagimet Investigative Site

    Miramar, Florida · Recruiting

  • Sagimet Investigative Site

    Sweetwater, Florida · Recruiting

  • Sagimet Investigative Site

    Lincolnshire, Illinois · Recruiting

  • Sagimet Investigative Site

    Indianapolis, Indiana · Recruiting

  • Sagimet Investigative Site

    New Albany, Indiana · Recruiting

  • Sagimet Investigative Site

    Plainfield, Indiana · Recruiting

  • Sagimet Investigative Site

    Brighton, Massachusetts · Recruiting

  • Sagimet Investigative Site

    Ann Arbor, Michigan · Recruiting

  • Sagimet Investigative Site

    Clinton Township, Michigan · Recruiting

  • Sagimet Investigative Site

    Saint Joseph, Missouri · Recruiting

  • Sagimet Investigative Site

    Omaha, Nebraska · Recruiting

  • Sagimet Investigative Site

    Portsmouth, New Hampshire · Recruiting

  • Sagimet Investigative Site

    Robbinsville, New Jersey · Recruiting

  • Sagimet Investigative Site

    Wilmington, North Carolina · Recruiting

  • Sagimet Investigative Site

    Columbus, Ohio · Recruiting

  • Sagimet Investigative Site

    East Greenwich, Rhode Island · Recruiting

  • Sagimet Investigative Site

    Greenville, South Carolina · Recruiting

  • Sagimet Investigative Site

    Murfreesboro, Tennessee · Recruiting

  • Sagimet Investigative Site

    Nashville, Tennessee · Recruiting

  • Sagimet Investigative Site

    College Station, Texas · Recruiting

  • Sagimet Investigative Site

    El Paso, Texas · Recruiting

  • Sagimet Investigative Site

    Houston, Texas · Recruiting

  • Sagimet Investigative Site

    San Antonio, Texas · Recruiting

  • Sagimet Investigative Site

    Spokane, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.